Trinity Biotech Net Worth
Trinity Biotech Net Worth Breakdown | TRIB |
Trinity Biotech Net Worth Analysis
Trinity Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Trinity Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Trinity Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Trinity Biotech's net worth analysis. One common approach is to calculate Trinity Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Trinity Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Trinity Biotech's net worth. This approach calculates the present value of Trinity Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Trinity Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Trinity Biotech's net worth. This involves comparing Trinity Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Trinity Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Trinity Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Trinity Biotech's net worth research are outlined below:
| Trinity Biotech plc had very high historical volatility over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (24.02 M) with profit before overhead, payroll, taxes, and interest of 21.13 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (11.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from seekingalpha.com: Trinity Capital declares 0.51 dividend |
Trinity Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Trinity Biotech plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Trinity Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 4th of July 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Trinity Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Trinity Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Trinity Biotech plc backward and forwards among themselves. Trinity Biotech's institutional investor refers to the entity that pools money to purchase Trinity Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Integrys Wealth Advisors Llc | 2024-12-31 | 10 K | Hartland & Co | 2024-12-31 | 10 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 K | Rhumbline Advisers | 2024-12-31 | 1.8 K | Simplex Trading, Llc | 2024-12-31 | 1.4 K | Jones Financial Companies Lllp | 2024-12-31 | 468 | Bank Of America Corp | 2024-12-31 | 240 | Atlantic Trust Group, Llc | 2024-12-31 | 222 | Atwood & Palmer Inc | 2024-12-31 | 20.0 | Perceptive Advisors Llc | 2024-12-31 | 1.8 M | Hunter Associates Inc. | 2024-12-31 | 378.6 K |
Follow Trinity Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.16 M.Market Cap |
|
Project Trinity Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.48) | |
| Return On Capital Employed | (0.55) | (0.52) | |
| Return On Assets | (0.36) | (0.35) | |
| Return On Equity | 0.90 | 0.95 |
When accessing Trinity Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Trinity Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Trinity Biotech's profitability and make more informed investment decisions.
Please note, the presentation of Trinity Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Trinity Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Trinity Biotech's management manipulating its earnings.
Evaluate Trinity Biotech's management efficiency
Trinity Biotech plc has return on total asset (ROA) of (0.0819) % which means that it has lost $0.0819 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.95, whereas Return On Tangible Assets are projected to grow to (0.48). At present, Trinity Biotech's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 69.5 M, whereas Total Assets are forecasted to decline to about 64.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.14) | (0.13) | |
| Tangible Book Value Per Share | (0.30) | (0.29) | |
| Enterprise Value Over EBITDA | (14.67) | (15.41) | |
| Price Book Value Ratio | (0.79) | (0.75) | |
| Enterprise Value Multiple | (3.00) | (3.14) | |
| Price Fair Value | (0.79) | (0.75) | |
| Enterprise Value | 5.5 B | 3.9 B |
The operational strategies employed by Trinity Biotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 1.8442 | Revenue | Quarterly Revenue Growth 0.032 | Revenue Per Share | Return On Equity |
Trinity Biotech Earnings per Share Projection vs Actual
Trinity Biotech Corporate Management
| Simon Dunne | Chief Officer | Profile | |
| Fernando Devia | Ex Sales | Profile | |
| Eibhlin Kelly | Chief Officer | Profile | |
| Aris Kekedjian | CEO Chairman | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share | Quarterly Revenue Growth 0.032 | Return On Assets |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.